Fierce Biotech20m
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps eneboparatide on track to come to market, but the lack of numbers in the readout ...
The Manila Times27m
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...
Gene Hackman's home was 'a mess' before his tragic death with worrying detail about his dogs
Gene Hackman's home in Santa Fe was reportedly in a state before his tragic death last month, with a friend saying his wife ...
The Manila Times27m
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
Collegium also announced today the appointments of three new executive leaders as the Company drives a new phase of growth: David Dieter, as Executive Vice President, General Counsel; Jane Gonnerman ...